Pharmacodynamic evidence for tedizolid use in Mycobacterium avium lung disease [PDF]
IJTLD OpenOBJECTIVE: On guideline-based therapy for Mycobacterium avium complex (MAC) lung disease (LD), ∼50%–60% of patients suffer recalcitrant disease. Tedizolid is a promising agent based on the intracellular hollow fibre model of MAC-LD (HFS-MAC) using the ...
D. Deshpande, S. Srivastava, T. Gumbo
doaj +2 more sources
LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring [PDF]
Drug Design, Development and TherapyNa Zhang,* Nan Bai,* Ying Wang, Beibei Liang, Yun Cai Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors ...
Zhang N, Bai N, Wang Y, Liang B, Cai Y
doaj +2 more sources
Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021 Cutaneous non-tuberculous mycobacterial (NTM) infections are an emerging infectious disease and require a protracted course of combination antibiotics. Antimicrobial choice is limited by resistance and toxicity.
Timothy David Shaw +3 more
doaj +5 more sources
Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption [PDF]
Clinical and Translational SciencePenetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood–brain barrier, which is the most ...
Marin Lahouati +5 more
doaj +2 more sources
Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis [PDF]
Antimicrobial Stewardship & Healthcare EpidemiologyOxazolidinone antibiotics—linezolid and tedizolid—are often used to treat multidrug-resistant infections. They are highly bioavailable and ideal for transition to enteral therapy when appropriate.
Adam Greenfield +4 more
doaj +2 more sources
In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
Infection and Drug Resistance, 2022 Huiyun Zhang,1 Wenya Hua,1 Siran Lin,1 Yu Zhang,1 Xinchang Chen,1 Shiyong Wang,1 Jiazhen Chen,1 Wenhong Zhang1– 3 1Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center
Zhang H +7 more
doaj +3 more sources
New and old oxazolidinones: tedizolid vs. linezolid [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2017 Tedizolid is a novel oxazolidinone that has been recently approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive pathogens, including MRSA.
Dekhnich A.V., Hachatryan N.N.
doaj +1 more source
Study on the Efficacy and Safety of Tedizolid in Japanese Patients [PDF]
AntibioticsBackground/Objective: Tedizolid (TZD), an oxazolidinone, causes fewer adverse events than linezolid (LZD). However, studies on the long-term efficacy and safety of TZD, particularly in patients with hematological malignancies (HMs), remain limited.
Kazuhiro Ishikawa +2 more
doaj +2 more sources
Pharmacokinetics and Pharmacodynamics of Tedizolid [PDF]
Clinical Pharmacokinetics, 2022 Tedizolid is an oxazolidinone antibiotic with high potency against Gram-positive bacteria and currently prescribed in bacterial skin and skin-structure infections. The aim of the review was to summarize and critically review the key pharmacokinetic and pharmacodynamic aspects of tedizolid.
Khalid Iqbal +2 more
openaire +3 more sources
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? [PDF]
PharmaceuticsMultidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity.
Ricky Hao Chen +4 more
doaj +2 more sources